Worsening earnings environment due to higher imported raw-material prices and price-cutting requests from generic drug manufacturers
First written in FY2018-Q2. 8 of 16 entries say "Materialised", first in FY2018-Q3. Latest entry: FY2024.
Astena Holdings moved to the "Worse" side of this theme in 2018, 4 years before the typical company in this theme (2022).
0 other companies' latest entry also says "Mitigated".
- FY2024MitigatedAnnual report
「Meanwhile, for products manufactured in-house, passing through price increases for nearly all products was successful, resulting in a substantial improvement in profit margins.」
While cost pressures from raw materials, foreign exchange and other factors continued, price increases were passed through for nearly all in-house-manufactured products, raising profit margins. - FY2024-Q2MitigatedAnnual report
「Sales of manufactured and marketed products also remained strong, and together with the effects of price revisions and other measures, this led to higher profit margins.」
While raw material, logistics and other costs put pressure on earnings, the effects of price revisions and other measures were cited as having improved profit margins for manufactured and marketed products. - FY2023-Q2MaterialisedAnnual report
「Profitability declined because prescription drug companies cannot immediately pass higher raw material and energy costs through to selling prices.」
Higher raw material and energy costs and delays in passing through price increases emerged as lower profitability in the pharmaceutical business. - FY2023-Q1MaterialisedAnnual report
「Meanwhile, profitability declined due to the impact of soaring raw material and utilities costs.」
Higher costs for raw materials, utilities and other items emerged as lower profitability in the pharmaceutical business. - FY2022WorsenedAnnual report
「In the pharmaceutical raw materials market, the environment continues to require ongoing pricing measures due to the sharp depreciation of the yen and increases in energy and other costs.」
Earnings pressure from higher imported raw material prices and price-cutting demands deteriorated into the need for ongoing pricing measures as a result of the sharp depreciation of the yen and higher energy costs. - FY2022-Q1RestatedAnnual report
「In the pharmaceutical raw materials field, amid the lack of an expected recovery in demand due to the impact of COVID-19, we focused on responding to higher raw material costs through pricing, delivering new imported generic active pharmaceutical ingredients and intermediates, and expanding sales of in-house products.」
While earnings pressure from higher raw material costs continues, the Group is pursuing pricing measures. - FY2020MaterialisedAnnual report
「In the pharmaceutical raw materials market, the impact of COVID-19 became apparent in the form of fewer hospital prescriptions, delays in delivery and additional transport costs for imported raw materials, and moves to switch to domestic procurement.」
Fewer hospital prescriptions, delays in delivery and higher transport costs for imported raw materials, and moves to switch to domestic procurement actually occurred. - FY2020-Q2MaterialisedAnnual report
「In the pharmaceutical raw materials market, the impact of COVID-19 became apparent in the form of fewer hospital prescriptions, delays in delivery and additional transport costs for imported raw materials, and moves to switch to domestic procurement.」
COVID-19 resulted in fewer hospital prescriptions, delays in delivery and higher transport costs for imported raw materials, and actual moves to switch to domestic procurement. - FY2020-Q1MaterialisedAnnual report
「In the fine chemicals business, amid delays in delivery and difficulty procuring overseas raw materials due to the spread of COVID-19, the Group promoted multiple sourcing of raw materials to meet firm demand for pharmaceutical raw materials.」
Delays in delivery and difficulty procuring overseas raw materials actually occurred as the spread of COVID-19 continued, and the Group responded through multiple sourcing. - FY2019MitigatedAnnual report
「The Group promoted multiple sourcing of raw materials. At the same time, in response to pressure from higher costs due to increases in raw material and logistics costs, it worked to improve profitability by adjusting the selling prices of existing products. As a result, ...adjustments to selling prices also gradually progressed.」
While higher costs and difficulty procuring raw materials continued, multiple sourcing and selling-price adjustments progressed, and measures addressing profitability were reflected in actual results. - FY2019-Q3RestatedAnnual report
「Although higher costs reduced profits, the launch of transactions involving new medium-molecule pharmaceuticals, adoption of newly developed generic drugs, firm sales of existing pharmaceutical raw materials and higher sales of contract fine chemicals contributed to performance, resulting in substantial overall growth in both sales and profit.」
While lower profits due to higher costs continued, overall sales and profit grew as a result of new transactions and product adoptions and higher sales of contract products. - FY2019-Q2MaterialisedAnnual report
「As a result, some raw materials from China became difficult to obtain, but the Group worked to stabilise supply by proposing alternative raw materials, and sales of existing pharmaceutical raw materials remained firm.」
The difficulty of obtaining raw materials from China materialised, and the Group responded by stabilising supply through proposals for alternative raw materials. - FY2019-Q1MaterialisedAnnual report
「In the pharmaceutical raw materials business, while higher logistics costs, cost increases associated with China's environmental regulations and difficulty procuring raw materials have emerged, manufacturers and distributors continue to make strong demands for price reductions, making it difficult to secure profits,」
Higher logistics costs, cost increases associated with China's environmental regulations, difficulty procuring raw materials and price-cutting demands from manufacturers and distributors have emerged as actual conditions in the earnings environment. - FY2018WorsenedAnnual report
「In its in-house manufacturing operations, the Group also worked to adjust selling prices in response to higher costs and difficulty procuring raw materials caused by high crude oil prices and China's environmental regulations.」
Higher crude oil prices, cost increases associated with China's environmental regulations and difficulty procuring raw materials were identified as specific earnings pressures. The Group is also working to adjust selling prices. - FY2018-Q3MaterialisedAnnual report
「In the pharmaceutical ingredients sector, amid negative factors including a slowdown in the growth of generic drugs' volume share and surging crude oil and imported raw material prices,」
Higher crude oil and imported raw material prices became actual negative factors, and rising raw material costs affected operating profit. - FY2018-Q2First statedAnnual report
「In the pharmaceutical raw materials market, substantial price increases for imported raw materials and strong demands from generic drug manufacturers for price reductions following the April 2018 drug-price revision have caused the market's earnings environment to deteriorate.」
Higher prices for imported raw materials and price-cutting demands from generic drug manufacturers following the drug-price revision were identified for the first time as factors deteriorating the earnings environment in the pharmaceutical raw materials market.